LDL-C
Low-density lipoprotein cholesterol — the traditional measure of 'bad' cholesterol concentration.
Optimal Range
< 100 mg/dL (standard) · < 70 mg/dL (high risk)
Risk-Stratified Targets
| Population / Context | Target |
|---|---|
| General population | < 100 mg/dL |
| Moderate cardiovascular risk | < 100 mg/dL |
| High cardiovascular riskDiabetes, 10-year ASCVD risk > 7.5% | < 70 mg/dL |
| Very high risk (established CVD)Per 2019 ESC/EAS guidelines | < 55 mg/dL |
| Familial hypercholesterolemiaIn addition to absolute target | ≥ 50% reduction from baseline |
Why It Matters
Elevated LDL-C contributes to arterial plaque buildup. While useful, LDL-C measures cholesterol mass, not particle count — ApoB and LDL-P are more precise indicators of atherogenic risk.
Understanding LDL-C
LDL cholesterol has been the cornerstone of cardiovascular risk assessment for decades, and for good reason — the evidence linking elevated LDL-C to atherosclerotic cardiovascular disease is among the strongest in all of medicine. Mendelian randomization studies, prospective cohorts, and randomized controlled trials with statins all converge on the same conclusion: lower LDL-C translates to lower cardiovascular event rates, with a roughly 22% reduction in major cardiovascular events per 1 mmol/L (39 mg/dL) reduction.
However, LDL-C has an important limitation: it measures the total mass of cholesterol carried by LDL particles, not the number of particles. This means it can underestimate risk in people with many small, dense LDL particles (common in metabolic syndrome and type 2 diabetes) and overestimate risk in those with fewer, larger particles. When LDL-C and ApoB diverge, cardiovascular risk follows ApoB. For this reason, many longevity-focused clinicians use ApoB as the primary target and LDL-C as a supporting metric.
Risk-stratified targets for LDL-C have shifted dramatically in recent years. The 2019 ESC/EAS guidelines introduced an aggressive < 55 mg/dL target for very high-risk patients. This is based on the principle of 'lower is better' with no identified lower threshold of benefit — supported by studies of individuals with lifelong genetically low LDL-C who show markedly reduced cardiovascular disease without adverse effects.
Key Research
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
Baigent C et al. (CTT Collaboration) · Lancet (2010)
Key finding: Each 1 mmol/L reduction in LDL-C reduces major vascular events by approximately 22%, with benefits proportional to the absolute reduction achieved.
2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach F et al. · Eur Heart J (2020)
Key finding: Introduced LDL-C < 55 mg/dL target for very high-risk patients and established ApoB as a secondary treatment target.